[Edaily Reporter Shin Ha-yeon ] △SK hynix(000660) - Q2 revenue forecast at 87.1 trillion won (up 292.0% YoY), operating profit at 67.6 trillion won (up 638.0% YoY) -With robust HBM demand driven by Big Tech, coupled with large-scale CAPEX, the company is expected to benefit from HBM △LigaChem Biosciences(141080) - Expectations for progress in clinical development by partners, entry of the company’s own pipeline into clinical trials, and technology exports -Plans to file approximately 10 IND applications from its new ADC drug pipeline by 2027 △Hanwha Ocean(042660) -Profitability in the merchant ship segment is expected to continue improving as low-priced orders are cleared and revenue from high-priced vessels is recognized in earnest - Expectations for expanded orders for specialty vessels, such as Canada’s CPSP and South Korea’s KDDX, as well as increased orders for offshore plants
(Photo: Blind)
One of the concerns facing the Lee Jae-myung administration is the decline in support among young people. According to Gallup Korea’s presidential job approval ratings, the approval…
The KRX Health Care Index rose 4.53% from the previous session on Oct. 1, signaling a rare tailwind for South Korea’s pharmaceutical and biotech sector. Among the gainers, GIInnovation and G2GBio drew…
(Graphic: ChatGPT)
“While existing ex vivo chimeric antigen receptor T-cell (CAR-T) therapies are personalized treatments that require cell collection from each patient for manufacturing, the in v…
